Although several feasibility studies have demonstrated the safety of adjuvant concurrent chemoradiotherapy (CRT) for locally advanced or incompletely resected non-small-cell lung cancer (NSCLC), it remains uncertain whether this approach is superior to sequential chemotherapy followed by postoperative radiotherapy (C→PORT). We sought to determine the most effective treatment sequence.
INTRODUCTION
In patients with resected locally advanced nonsmall-cell lung cancer (NSCLC), adjuvant chemotherapy has led to improved overall survival (OS) 1, 2 and is considered standard of care. The benefit of postoperative radiotherapy (PORT) has been controversial. In a meta-analysis of multiple older clinical trials, PORT was associated with worse outcomes in patients with early-stage disease. 3 However, several studies have indicated patients with pN2 disease [3] [4] [5] [6] [7] or incomplete resection may benefit from PORT. 8 Current guidelines state indications for PORT include positive surgical margins or pN2 disease. 9, 10 The ongoing phase III European Organisation for Research and Treatment of Cancer trial EORTC 22055-08053, Radiation Therapy in Treating Patients With Non-Small-Cell Lung Cancer That Has Been Completely Removed by Surgery (LUNG ART) seeks to determine if PORT using modern treatment techniques is beneficial in pN2 disease.
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Several randomized studies have shown benefit for more aggressive therapy for patients with unresectable cN2 locally advanced NSCLC identified on initial staging studies. Sequential chemotherapy with 5 weeks of platinum-based Author affiliations and support information (if applicable) appear at the end of this article.
chemotherapy followed by RT is superior to RT alone. 12, 13 Other trials have shown that concurrent chemoradiotherapy (CRT) offers a survival advantage over sequential regimens in the unresectable setting, making CRT the standard of care in patients with unresectable disease with adequate performance status and minimal weight loss. 14, 15 Although retrospective data suggest adding chemotherapy to PORT improves outcomes, 16 the preferred sequencing of chemotherapy and PORT in the adjuvant setting is controversial. Current guidelines advise sequential chemotherapy followed by PORT for patients with pN2 disease with negative margins (R0) and suggest CRT for patients with positive margins. 9, 10 However, given the lack of randomized data and proven benefit of CRT in the definitive treatment setting, we sought to determine the most effective treatment sequence.
PATIENTS AND METHODS

Patient Population
We used National Cancer Database (NCDB) registry data for patients with NSCLC diagnosed between 2006 and 2012 (most recent dataset available at time of study). The NCDB is a nationwide oncology outcomes database that captures 70% of all newly diagnosed cancer cases in the United States and provides access to data subsets to Commission on Cancer-accredited programs via an online application process.
From this dataset, we selected a cohort of patients with nonmetastatic disease who had undergone at least a lobectomy. The study cohort was limited to patients with adenocarcinoma or squamous cell carcinoma who had received adjuvant multiagent chemotherapy and external-beam RT to the lung, chest, or lymph nodes. Those without follow-up information or who had died within 3 months of diagnosis were excluded. Appendix Table A1 (online only) lists NCDB data codes used.
We created two cohorts of patients based on National Comprehensive Cancer Network (NCCN) guidelines on indications for adjuvant chemotherapy and PORT.
10 Cohort one included patients with R0 resection and pT1-T3 and pN2 disease who had received total radiation doses of 45, 50, 50.4, or 54 Gy in standard 1.8-or 2.0-Gy fractionation. 6, 10 Cohort two included patients with microscopic (R1) or grossly (R2) positive margins with pT1-T3 and pN0-N2 disease who received total radiation doses of 45, 50, 50.4, 54, 59.4, 60, 66, 66.6, or 70 Gy in standard 1.8-or 2.0-Gy fractionation (Fig 1) . A higher dose range was used for cohort two based on recommendation for dose escalation for positive margins. 8, 10 Patients were classified as having received sequential chemotherapy followed by radiation (C→PORT group) if they received the first cycle of chemotherapy within 90 days after surgery and a minimum of 6 weeks before RT, based on NCCN recommendation of at least two cycles of adjuvant chemotherapy. 10 Patients were also included in the C→PORT group if they had received the first cycle of chemotherapy within 90 days after surgery and up to a maximum of 18 weeks prior to starting RT; this was based on 4 cycles of adjuvant chemotherapy and allowing up to 6 weeks after chemotherapy before PORT as permitted in the ongoing LUNG ART trial.
11 Patients were classified as having received CRT if they started RT within 90 days after surgery and received the first cycle of chemotherapy within 14 days before or after starting RT (Fig 2) . Patients who completed RT before receiving their first cycle of chemotherapy were excluded.
Patient characteristics for analysis included age, sex, race, treatment facility type, Charlson comorbidity score (CCS), tumor grade, histology, tumor size, pathologic T stage, pathologic N stage, surgical margin status, surgery type, and total radiation dose. Smoking information is not available in the NCDB. The primary end point was OS based on time of diagnosis until date of death. Statistical Analysis x 2 analysis was used to compare categorical demographic and tumor characteristics between groups. t test was used to compare continuous variables between groups. Univariable (UVA) and multivariable analysis (MVA) logistic regression modeling were used to identify predictors for treatment sequence group, reported as odds ratios (ORs). UVA and MVA Cox proportional hazard modeling were used to identify factors associated with OS, reported as hazard ratios (HRs). The respective MVA models were created by including all covariates and then removing each covariate with a P value . .2, starting with the covariate with the largest P value, in a reverse stepwise fashion. Categorical covariates were included in the final model if one of the covariate levels in comparison with the reference level had a P value , .2.
17,18
Propensity score (PS) analysis was used to account for differences in baseline patient characteristics between the C→PORT and CRT groups. Matching was performed based on patient characteristics and disease factors that included age, sex, CCS, tumor size, histology, grade, pathologic T stage, pathologic N stage, margin status, surgery type, treatment facility type, and radiation dose according to the method previously described by Rosenbaum and Rubin (Appendix, online only). [19] [20] [21] After matching, a shared-frailty or matched-sample UVA Cox regression model was applied to the matched groups to estimate the effect of treatment sequence (C→PORT v CRT) on survival. Forest plots were generated after PS matching using UVA Cox regression to analyze subgroup interactions. All analyses were performed using the STATA 14.2 statistical package (STATA, College Station, TX).
RESULTS
Cohort One
A total of 747 patients with R0 resection and pN2 disease were included in the analysis. Patient characteristics are listed in Table 1 . Fifty-nine percent of patients in cohort one received C→PORT. The mean age of patients in cohort one was 63.5 years. Patients in the CRT group had more medical comorbidities (ie, CCS . 0) than those in the C→PORT group (CRT group, 46% v C→PORT group, 31%; P , .01). Most patients had moderate (46%) or poorly differentiated (47%) tumors, and slightly more patients in the CRT group had poorly differentiated tumors compared with those in the C→PORT group (51% v 44%, respectively; P = .10). The most common histology was adenocarcinoma, although more patients in the CRT group had squamous cell histology compared with those in the C→PORT group (CRT, 27% v C→PORT, 17%; P , .01). On average, tumors in the C→PORT group were smaller than those in the CRT group (37.2 v 46.2 mm, respectively; P = .07). Most patients had pT2 tumors (59%) and had undergone lobectomy (91%). There was no difference in radiation dose between those in the C→PORT and CRT groups, and the overall median dose was 50.4 Gy (interquartile range [IQR], 50-50.4 Gy).
Patients with more medical comorbidities (ie, CCS $ 1) were more likely to receive CRT than C→PORT (OR, 1.7; P , .01; Table 2 ). Additionally, increasing tumor size was predictive for receipt of CRTover C→PORT (OR, 1.01; P = .02). In contrast, race other than white, black, or Hispanic (OR, 0.3; P = .05), pT3 tumors (OR, 0.5; P = .04), and adenocarcinoma histology (OR, 0.6; P = .02) were predictive for receipt of C→PORT.
On Cox MVA (Appendix Table A2 , online only), CCS $ 1 (HR, 1.25; P = .05), pT2 (HR, 1.46; P , .01), pT3 (HR, 1.16; P = .01), and CRT (HR, 1.45; P , .01) were associated with increased risk of death. Women had improved OS (HR, 0.79; P = .04). To test for CCS interaction, we performed a Cox MVA for patients with CCS of 0 and found CRT to be associated with increased mortality (HR, 1.60; P = .001). When limited to patients with CCS $ 1, the effect of CRTon survival lost statistical significance (HR, 1.25; P = .19).
The use of CRT for patients with negative margins and pN2 disease declined between 2006 and 2012, whereas the use of C→PORT increased (Fig 3A) . In 2006, 53% of patients received C→PORT and 47% received CRT. In 2012, 63% of patients received C→PORT compared with 37% who received CRT.
In cohort one, the C→PORT group had a median follow-up of 33.5 months and a median OS of 58.8 months (95% CI, 53.7 to 69.4 months), compared with the CRT group, which had a median follow-up of 32.5 months and a median OS of 40.4 months (95% CI, 35.8 to 49.4 months; log-rank P , .001; Fig 4A) . At last follow-up, 178 patients had died and 263 were alive in the 
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C→PORT group, and 172 had died and 134 were alive in the CRT group. After PS matching, 510 patients were available for analysis. The C→PORT and CRT groups were well balanced for demographic and cancer characteristics (Table 3) . For the C→PORT group, the median follow-up was 31.5 months and median OS was 56.9 months (95% CI, 49.6 to 69.4 months), compared with a median follow-up of 32.9 months and median OS of 41.5 months (95% CI, 36.7 to 50.4 months) for the CRT group, which remained statistically significant (Fig 4B) . The CRT group had an increased risk of death compared with the C→PORT group (HR, 1.35; 95% CI, 1.05 to 1.73; P = .019). After PS matching, at last follow-up, 110 patients had died and 145 were alive in the C→PORT group, whereas 144 patients had died and 111 were alive in the CRT group. On subgroup analysis (Appendix Fig A1, online only) , no subgroup had a significant improvement with CRT, whereas outcomes for CCS of 0, poorly differentiated tumors, pT2 disease, lobectomy, and doses of 45 or 54 Gy favored C→PORT. 121  27  87  28  208  28  8  12  22  11  30  11  pT2  258  59  180  59  438  59  43  62  92  44  135  49  pT3  62  14  39  13  101  14  18  26  94  45  112  40  Total  441  100  306  100  747  100  69  100  208  100  277  100  Pathologic N stage  NA  .02  pN0  NA  15  22  78  38  93  34  pN1  NA  25  36  76  37  101  36  pN2  441  100  306  100  747  100  29  42  54  26  83  30  Total  441  100  306  100  747  100  69  100  208  100  277  100  Margin status  NA  .24  R0  441  100  306  100  747  100  NA  R1  NA  67  97  194  93  261  94  R2  NA  2  3  14  7  16  6  Total  441  100  306  100  747  100  69  100  208  100  277  100  Type of surgery performed  .64  .83  Lobectomy  405  92  278  91  683  91  59  86  180  87  239  86  Pneumonectomy  36  8  28  9  64  9  10  14  28  13  38  14  Total  441  100  306  100  747  100  69  100  208  100  277 .39
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Type of surgery Lobectomy Table 1 . In cohort two, 25% of patients received C→PORT, and 75% received CRT. The average patient age was 63.6 years. Most patients had moderate (45%) or poorly differentiated (50%) tumors; the most common histology overall was adenocarcinoma (57%). More patients in the CRT group had squamous cell histology (48%) compared with those in the C→PORT group (28%; P = .01). Overall, the average tumor size was 49.0 mm. The most common T stage was pT2; however, more patients in the CRT group had pT3 tumors (45%) compared with those in the C→PORT group (26%; P = .02). More patients in the C→PORT group had pN2 disease (42%) compared with those in the CRT group (26%; P = .02). A vast majority of patients had R1 resection (94%), and although not statistically significant, more patients in the CRT group had R2 resection (7%) compared with those in the C→PORT group (3%; P = .24). Lobectomy (86%) was the most common surgery. Patients in the C→PORT group had a lower total radiation dose than those in the CRT group (C→PORT, median was 59.4 Gy; IQR, 50.4-60 Gy v CRT, median was 59.4 Gy; IQR, 54-60 Gy; P = .01).
On UVA, predictive factors for receipt of C→PORT included pN2 disease (OR, 0.4; P = .01) and adenocarcinoma histology (OR, 0.5; P = .01; Table 2 ). These factors remained predictive on MVA. On Cox MVA (Appendix Table A3 , online only), increasing age (HR, 1.02 per year; P = .02) and undifferentiated histology (HR, 6.87; P = .01) were associated with worse OS.
The use of CRT for this cohort increased from 2006 to 2012, whereas the use of C→PORT decreased (Fig 3B) , coincident with changes to NCCN guidelines. In 2006, 33% of patients received C→PORT compared with 19% in 2012, in contrast to the 67% receiving CRT in 2006 compared with 81% in 2012.
For cohort two, the C→PORT group had median follow-up time of 32.9 months and median OS of 42.6 months (95% CI, 32.4 to 59.5 months), compared with the CRT group, which had a median follow-up of 27.0 months and median OS of 38.5 months (95% CI, 31.1 to 46.9 months; log-rank P = .42; Fig 4C) . At last follow-up, 40 patients had died and 29 were alive in the C→PORT group, whereas 119 had died and 89 were alive in the CRT group. After PS matching, 128 patients were available for analysis. Groups C→PORT and CRT were well balanced on demographic and cancer characteristics (Table 3 ). The C→PORT group had a median follow-up of 31.5 months and median OS of 38.3 months (95% CI, 27.2 to 59.5 months), compared with a median follow-up of 24.2 months and median OS of 33.8 months (95% CI, 18.8 to 47.9 months) for the CRT group (Fig 4D) . There remained no statistical difference in OS between the CRT and C→PORT groups (HR, 1.35; 95% CI, 0.86 to 2.13; P = .19). After PS matching, at last follow-up, 37 patients had died and 27 were alive in the C→PORT group, whereas 41 had died and 23 were alive in the CRT group. On subgroup analysis (Appendix Fig A2, online only) , no factors were significantly associated with better survival based on treatment sequence.
DISCUSSION
For patients with pN2 disease and negative margins, sequential C→PORT was associated with superior survival compared with CRT. For patients with positive margins, there was no statistical difference in survival between treatment sequencing options. These findings remained consistent after PS-matched analysis.
In the current American Society for Radiation Oncology evidence-based clinical practice guideline, Rodrigues et al 9 state that "given the demonstrated overall survival associated with CT (chemotherapy) and lack of overall survival benefit with radiation therapy (for R0 N2 disease), adjuvant radiation therapy should be delivered sequentially after CT in order not to interfere with CT delivery because of a risk of combined chemoradiation side effects that can lead to potential treatment breaks or deintensification." 9(p152) More recently, an NCDB analysis by Robinson et al 7 found that modern PORT in addition to adjuvant chemotherapy was associated with improved OS in R0 pN2 disease, suggesting chemotherapy alone is not sufficient for these patients.
In the definitive setting, CRT was shown to be superior to sequential chemotherapy followed by thoracic radiotherapy (C→TRT) in the Radiation Therapy Oncology Group phase III trial, Sequential Versus Concurrent Chemoradiation for Stage III NonSmall-Cell Lung Cancer (RTOG 9410), with a 6% improvement in 5-year survival. 15 However, patients in the CRT arm had worse grade $ 3 acute toxicities (91%) than those in the C→TRT arm (86%), whereas late toxicities were similar. Most significantly, the rate of grade $ 3 esophageal toxicities was 22% with CRT versus 4% with C→TRT. Mucositis, nausea or vomiting, and other nonhematologic toxicities were also higher in the CRT arm. Thus, one possible explanation for our finding that C→PORT was associated with improved OS compared with CRT is the lower toxicity with sequential treatment. Furthermore, patients who are recovering from the acute adverse effects of surgical resection may be less able to tolerate the higher toxicity of CRT. These patients harbor, at most, microscopic rather than gross disease, and the improved local disease control seen with CRT for unresectable locally advanced NSCLC 15 may not translate into improved outcomes in the postoperative setting. Even though CRT is likely more toxic, patients in cohort one with more comorbidities were more likely to have received CRT. However, after PS matching, the CRT group still had worse OS, which suggests that the treatment sequence affects survival regardless of preexisting comorbidities.
A recent NCDB analysis found that PORT was associated with improved survival in patients with stage II or III disease with positive margins, but it did not assess the effect of sequencing RT and chemotherapy. 8 Although there is no randomized evidence, current guidelines recommend CRT for positive surgical margins (R1-2). 9, 10 We found a 4.1-month improvement in median OS for patients with positive margins receiving C→PORT compared with CRT, although this did not reach statistical significance. It is possible there were too few patients with R1-2 resection to detect a difference. Additionally, most patients in cohort two had microscopic positive margins rather than gross residual tumor, and it is patients with the latter who hypothetically might derive the most benefit from CRT. Furthermore, it is possible that the tumoricidal benefit of CRT for positive margins balances with the increased toxicity of this approach, and thus, there was not a detectable difference in OS based on treatment sequencing in the R1-2 cohort.
We also found that trends in use between 2006 and 2012 showed an increase in use of C→PORT for patients in cohort one (R0 pN2) and a decrease in use of CRT. For patients in cohort two Overall Survival (proportion) jco.org (R1-2 margin), use of CRT increased, whereas use of C→PORT decreased over time. These findings suggest practice patterns have shifted toward concordance with consensus guideline recommendations over time.
Our study has limitations. Data on recurrence, cancer-specific survival, type of chemotherapy, and number of cycles are not reported in the NCDB. Additionally, our study is a retrospective analysis of nonrandomized data, and although our analyses used PS-matching techniques to account for confounding as a result of measured covariates, confounding may have persisted among nonmeasured covariates; it is impossible to completely account for these limitations outside of a prospective randomized clinical trial. Although the NCDB captures a majority of cancer diagnoses, it is not a population-based database, and generalizability may be limited.
Despite these limitations, our study has several strengths. Although some treatment details are not specified in the NCDB, we only included patients who had received chemotherapy and RT at accepted time points after surgery to ensure we captured the 76  29  78  30  154  29  8  13  13  21  21  17  pT2  153  58  154  58  307  58  37  59  29  46  66  52  pT3  35  13  32  12  67  13  18  29  21  33  39  31  Total  264  100  264  100  528  100  63  100  63  100  126  100  Pathologic N stage  NA  .83  pN0  NA  15  24  15  24  30  24  pN1  NA  23  37  20  32  43  34  pN2  264  100  264  100  528  100  25  40  28  44  53  42  Total  264  100  264  100  528  100  63  100  63  100  126  100  Margin status  NA  .24  R0  264  100  264  100  528  100  NA  R1  NA  61  97  58  92  119  94  R2  NA  2  3  5  8  7  6  Total  264  100  264  100  528  100  63  100  63  100  126  100  Type surgery performed  .63  .57  Lobectomy  242  92  245  93  487  92  55  87  57  90  112  89  Pneumonectomy  22  8  19  7  41  8  8  13  6  10  14  11  Total  264  100  264  100  528  100  63  100  63  100  126  100  Total Abbreviations: C→ PORT, chemotherapy followed by postoperative radiotherapy; CCS, Charlson comorbidity score; CRT, concurrent chemoradiotherapy; IQR, interquartile range; NA, not applicable; PS, propensity score; SD, standard deviation.
appropriate populations of interest for our questions. We also clearly defined two clinically distinct patient cohorts and separately analyzed the data with results that are clinically relevant to each group. Additionally, we found consistent results in both cohorts after PS analyses that accounted for potential differences between comparison groups. Taken together, our results contribute to the literature and suggest that when PORT is administered to patients with R0 pN2 disease, there is a survival benefit with sequential C→PORT compared with CRT. We also found that sequential therapy is becoming the more frequent practice pattern over time for patients with R0 pN2 disease, and our results support this practice. In patients with positive margins, we found the use of CRT to have increased over time, although we did not clearly identify a superior sequencing option.
In conclusion, in the postoperative setting for patients with NSCLC with R0 resection and pN2 disease, sequential C→PORT was associated with improved OS compared with CRT. For patients with positive margins, there was not a clear association between treatment sequencing and survival. Abbreviations: C→PORT, chemotherapy followed by postoperative radiotherapy; CCS, Charlson comorbidity score; CRT, chemoradiotherapy; HR, hazard ratio; MVA, multivariable analysis; UVA, univariable analysis. Total dose, Gy No.
